Price$27.09-3.96 (-12.75%)
2026-03-042026-06-05
News · 26 weeks45+117%
2025-12-142026-06-07
Mix2590d
- Insider12(48%)
- SEC Filings6(24%)
- Other5(20%)
- Earnings2(8%)
Latest news
25 items- SECSEC Form SD filed by AtriCure Inc.SD - AtriCure, Inc. (0001323885) (Filer)
- PRAtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care ConferenceAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related c
- INSIDERDirector Prange Karen sold $85,950 worth of shares (3,000 units at $28.65), decreasing direct ownership by 10% to 26,373 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Prange Karen was granted 6,144 shares, increasing direct ownership by 26% to 29,373 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Telman Deborah H was granted 6,144 shares, increasing direct ownership by 28% to 28,328 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Yuen Maggie was granted 6,144 shares, increasing direct ownership by 54% to 17,515 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Johnson B Kristine was granted 6,144 shares, increasing direct ownership by 12% to 55,954 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Nachman Shlomo was granted 6,144 shares, increasing direct ownership by 33% to 24,655 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Groves Regina E was granted 6,144 shares, increasing direct ownership by 18% to 39,859 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Wehrwein Sven was granted 6,144 shares, increasing direct ownership by 18% to 40,518 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector White Robert S. was granted 6,144 shares, increasing direct ownership by 5% to 128,318 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- SECAtriCure Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - AtriCure, Inc. (0001323885) (Filer)
- INSIDERChief Scientific Officer Doraiswamy Vinayak sold $140,650 worth of shares (5,000 units at $28.13), decreasing direct ownership by 5% to 91,875 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
- SECSEC Form 10-Q filed by AtriCure Inc.10-Q - AtriCure, Inc. (0001323885) (Filer)
- SECAmendment: AtriCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K/A - AtriCure, Inc. (0001323885) (Filer)
- PRAtriCure Reports First Quarter 2026 Financial ResultsFirst Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, EnCompass® clamp, and AtriClip PRO-Mini® AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. "Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined exe
- SECAtriCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AtriCure, Inc. (0001323885) (Filer)
- PRAtriCure to Participate in the 2026 Bank of America Securities Health Care ConferenceAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, May 12, 2026, at 10:00 a.m. Pacific Daylight Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related cond
- PRAtriCure to Announce First Quarter 2026 Financial ResultsAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricur
- SECSEC Form DEFA14A filed by AtriCure Inc.DEFA14A - AtriCure, Inc. (0001323885) (Filer)
- SECSEC Form DEF 14A filed by AtriCure Inc.DEF 14A - AtriCure, Inc. (0001323885) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
- INSIDERChief Scientific Officer Doraiswamy Vinayak sold $149,150 worth of shares (5,000 units at $29.83), decreasing direct ownership by 5% to 96,875 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector White Robert S. exercised 10,000 shares at a strike of $14.99, increasing direct ownership by 9% to 122,174 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
ATRC FAQ
7 questionsWhat does AtriCure Inc. do?
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation...Where does ATRC stock trade?
AtriCure Inc. (ATRC) is listed on NASDAQ.What sector and industry is ATRC in?
AtriCure Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did AtriCure Inc. go public?
AtriCure Inc. (ATRC) completed its IPO in 2005.What are analysts saying about ATRC?
AtriCure Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-02-18. Recent price targets range from $3200.00 to $4000.00.What companies are similar to ATRC?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare ATRC side-by-side with any of them on Quantisnow.How can I track ATRC on Quantisnow?
Quantisnow aggregates AtriCure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATRC to receive live email and push alerts on every new disclosure.